AzTrials
AzTrials

Treatment for Metastatic or Locally Advanced Cervical CancerPhase 2NCT01613677

Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer

A Phase 2 study testing BKM120 in people with Treatment for Metastatic or Locally Advanced Cervical Cancer, run by Novartis Pharmaceuticals at 1 site in Brazil.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

This is a single arm open label phase II trial to evaluate the oral daily use of BKM 120 in patients with recurrent unresectable or metastatic cervical cancer after palliative cisplatin based regimen failure. A complete treatment cycle is defined as a 28 days period. Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
BKM120
Could I receive a placebo?
No, everyone receives an active treatment
How many people
0 participants
Where
1 siteBrazil
Study dates
Nov 2015to Sep 2017
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient has provided a signed Informed Consent Form (ICF) obtained prior to any screening procedure.
  • Female 18 years of age or older.
  • Histologically or cytologically confirmed recurrent unresectable or metastatic cervix squamous-cell carcinoma.
  • ECOG performance status 0-2
  • Adequate renal, hepatic and hematologic function:
  • ANC ≥1250/mm3;
Show all 15Show fewer
  • Platelet count ≥100,000/mm3;
  • Hemoglobin ≥ 9.0 g/dL
  • Creatinine ≤1.5X upper limits of normal or 24 hrs clearance ≥55ml/min;
  • Serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with well documented Gilbert Syndrome)
  • SGOT, SGPT ≤ 1.5 X upper limits of normal if no liver metastasis present;
  • SGOT, SGPT, alkaline phosphatase ≤ 3 X upper limits of normal if liver metastasis present;
  • Measurable disease by magnetic resonance imaging according to RECIST criteria.
  • Willingness and capacity in understand and comply with all of the trial planned procedures, including periodic medical visits, treatment plans and laboratory tests.
  • Negative serum pregnancy test during screening and negative urinary test for pregnancy within 48 hours before starting study treatment in women with childbearing potential

Who cannot join

  • Previous use of a PI3K inhibitor.
  • Brain or spinal cord compressive metastasis. Patients with appropriately treated brain or spinal metastasis and neurologically stable for at least 4 weeks can be included at discretion of investigator.
  • Concurrent malignancy other than non-melanoma skin cancer.
  • Concurrent clinical condition impeditive to be part of the study at the judgment of the investigator.
  • Patient has any of the following mood disorders as judged by the Investigator or a Psychiatrist, or meets the cut-off score of ≥ 10 in the PHQ-9 or a cut-off of ≥ 15 in the GAD-7 mood scale, respectively, or selects a positive response of '1, 2, or 3' to question number 9 regarding potential for suicidal thoughts ideation in the PHQ-9 (independent of the total score of the PHQ-9):
  • Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others)
Show all 35Show fewer
  • ≥ CTCAE grade 3 anxiety
  • Patients with acute or chronic liver, renal disease or pancreatitis.
  • Patients with diarrhea ≥ CTCAE grade 2.
  • Any of the following concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study:
  • ST depression or elevation of ≥ 1.5 mm in 2 or more leads;
  • Congenital long QT syndrome;
  • History or presence of sustained ventricular arrhythmias or atrial fibrillation;
  • Clinically significant resting bradycardia (< 50 beats per minutes);
  • QTc > 480 msec on screening ECG;
  • Complete left bundle branch block;
  • Right bundle branch block + left anterior hemi block (bifascicular block) ;
  • Unstable angina pectoris ≤ 6 months prior to starting study drug;
  • Acute myocardial infarction ≤ 6 months prior to starting study drug;
  • Other clinically significant heart disease such as congestive heart failure requiring treatment (NYHA Class III or IV) or uncontrolled hypertension;
  • Patients with clinical manifestation of diabetes mellitus (i.e. treated and/or with clinical signs) or steroid-induced diabetes mellitus or uncontrolled diabetes (Fasting glucose >120 mg/dL (HbA1c >8%).
  • Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol.
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).
  • Patients who have received corticosteroids ≤ 2 weeks prior to starting study drug.
  • Patient is currently being treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. Please refer to Table 5-8 for a list of prohibited CYP3A4 inhibitors and inducers.
  • Employing an effective method of birth control. (Women of child-bearing potential, defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months),
  • must have a negative serum pregnancy test during screening and negative urinary test for pregnancy within 48 hours before starting study treatment in women with childbearing potential).
  • Known diagnosis of human immunodeficiency virus (HIV) infection.
  • Patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator.
  • Patient has received pelvic and/or para-aortic radiotherapy ≤ 28 days prior to enrollment in this study or has not recovered from side effects of such therapy at the time of initiation of screening procedures
  • MRI study - additional exclusions to consider for an MRI study
  • Cardiac pacemaker
  • Ferromagnetic metal implants other than those approved as safe for use in MR scanners (Example: some types of aneurysm clips, schrapnel)
  • Claustrophobia
  • Obesity (exceeding the equipment limits)

Trial locations and contacts

1 site in 1 country.

Brazil1 site

  • Novartis Investigative Site

    Rio de Janiero, Rio de Janeiro, 20231-050

Other trials in Brazil

About this study

Official title: Phase II, Open Label, Non-randomized, Trial of BKM120 as Palliative Treatment for Metastatic or Locally Advanced Cervical Cancer After Failure to Platinum Based Regimen

This is a single arm open label phase II trial to evaluate the oral daily use of BKM 120 in patients with recurrent unresectable or metastatic cervical cancer after palliative cisplatin based regimen failure.

A complete treatment cycle is defined as a 28 days period.

Read the detailed description

Inclusion and exclusion criteria should be assessed in the pretreatment visit and the informed consent must be taken before treatment assignment. The diagnosis and extent of disease, the medical history, and the current medical condition should be recorded by the investigator in a pretreatment visit. Adverse events will be recorded including type, severity, graded by CTCAE V 3.0, seriousness and potential relation to the investigational drug.

The efficacy assessment will be done by MRI and recorded in the patients' clinical chart. Tumor dimension assessments will be performed at baseline through abdominal/pelvic magnetic resonance imaging, to be repeated in 3 months intervals and evaluated according RECIST criteria. The first cohort, composed by the 06 first patients, will undergo a separate positron-emission tomography (PET-CT) evaluation at baseline and 90 days apart.

Laboratory tests (hematology, blood chemistry), ECG and physical examination will be done on every visit.

Drug pharmacokinetics will not be assessed in this study. For the screening Baseline periods, see chart attached The treatment will be continued until progressive disease or intolerable toxicity

Being tested
BKM120
Keywords
advanced cervical cancer, BKM 120, progression free survival

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BKM120Drug

Study groups in NCT01613677
Study groupRoleWhat they receive
BKM120ExperimentalNot described
Receives: Drug: BKM120

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Toxicity profile by recording the frequency and severity of adverse events associated to the use of daily oral BKM 120 as assessed by NCI CTCAE v. 3.0

    Measured: 18 months

Secondary outcomes (1)

  1. Clinical benefit [complete response (CR), partial response (PR) rate and stable disease] according to RECIST criteria.

    Measured: 18 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jun 2012 (estimated)
  2. Study startNov 2015
  3. Primary completionSep 2017 (estimated)
  4. Study completionSep 2017 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01613677
Sponsor's protocol ID
CBKM120ZBR01
Status last verified
Feb 2016
First submitted
5 Jun 2012
Last updated
20 Apr 2017
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing BKM120 in people with Treatment for Metastatic or Locally Advanced Cervical Cancer, run by Novartis Pharmaceuticals at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 15 inclusion and 35 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 20 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Toxicity profile by recording the frequency and severity of adverse events associated to the use of daily oral BKM 120 as assessed by NCI CTCAE v. 3.0 (time frame: 18 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01613677.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2017.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in